When taken cumulatively, rare diseases still affect a substantial proportion of the population. In the USA and the UK, some 1 in 15 to 1 to 20 people suffer from a rare disease, although definitions of what constitutes a rare disease differ. For instance, in the US, the Rare Diseases Act of 2002 defines a rare disease as affecting fewer than 200,000 people, whereas in the EU, the European Commission has a different benchmark, defining diseases as rare when they affect more than 1 in 2,000 people. So, what causes rare diseases, and how are they treated? Rare diseases have numerous genetic, environmental, idiopathic and unknown causes. In some cases, they originally stem from genetic mutations, which are later activated by environmental triggers. Here's a deeper exploration of how rare diseases are caused or triggered:

Factores genéticos
Los factores genéticos son la causa principal de muchas enfermedades raras. Estas enfermedades suelen ser hereditarias y surgen cuando genes específicos mutan, alterando funciones corporales o causando problemas de desarrollo.

A veces, los factores genéticos de riesgo a largo plazo se "activan" por desencadenantes a corto plazo.

• Cystic Fibrosis: Related to mutations in the CFTR gene, this disease primarily affects the respiratory and digestive systems by producing thickened mucus. It's passed on through a recessive inheritance pattern.
• Huntington's Disease: A neurodegenerative condition, Huntingdon’s is attributed to mutations in the HTT gene. Children have a 50% chance of inheriting the disease if one parent has the mutated gene.
• Children have a 50% chance of inheriting the disease if one parent has the mutated gene.
• Phenylketonuria (PKU): Affecting fewer than1 in 10,000 babies, PKU derives from mutations in the PAH gene, leading to an impaired ability to break down amino acids.

Activadores medioambientales

Aunque la genética suele desempeñar un papel en el desarrollo de las enfermedades raras, los desencadenantes ambientales pueden exacerbar o iniciar su aparición. Los desencadenantes ambientales desempeñan un papel crucial, aunque misterioso, en el desarrollo de numerosas enfermedades comunes y raras.

He aquí algunos casos conocidos:

• Porphyria: Although having a genetic foundation, this disease group also reacts strongly to environmental triggers. Exposure to drugs, stress, sun, or certain foods can lead to an acute attack.
• Lupus: Affecting between 2 and 8 people per 100,000, Lupus has an underlying genetic risk, but external factors can instigate or worsen the disease. Sunlight, infections, and specific medications are known triggers.
• Paraneoplastic Pemphigus: While associated with cancers, trauma or specific

Causas desconocidas
En algunos casos, las enfermedades raras no tienen una causa fundamental ampliamente aceptada. Suelen tener orígenes multifactoriales que varían de un paciente a otro.

Entre las enfermedades raras con causas poco conocidas o desconocidas se incluyen:

• Reflex Sympathetic Dystrophy (RSD): A rare disease that causes chronic burning pain, the exact origins of RSD remain unknown. Injuries or surgical procedures can sometimes lead to its onset.

• Stiff Person Syndrome: Predominantly marked by muscle rigidity and spasms, this exceptionally rare disease – considered one of the rarest worldwide – is likely immune-system related.
• Chronic Fatigue Syndrome (CFS): CFS, though still considered rare, has become more common in recent times. It’s often associated with infection, but a conclusive cause has not been identified.

Según las estimaciones actuales, la ciencia conoce entre 6.000 y 8.000 enfermedades raras.

Apenas el 5% de estas enfermedades tienen tratamientos reconocidos. Si una enfermedad rara tiene un único tratamiento conocido, se denomina "tratamiento huérfano". Una mayoría significativa de los enfermos de enfermedades raras, junto con sus proveedores de asistencia sanitaria, se enfrentan a afecciones que actualmente carecen de vías terapéuticas concretas. De nuevo, aunque la tasa de incidencia de cada enfermedad rara es baja, el impacto acumulativo es alto, afectando a 1 de cada 15 personas de media.

El desarrollo de tratamientos para estas enfermedades presenta una serie de retos específicos. Dado el reducido número de personas diagnosticadas con una enfermedad rara concreta, resulta problemático realizar ensayos clínicos exhaustivos. Además, recaudar fondos para la investigación de enfermedades raras también es complicado. La financiación para la investigación de las enfermedades raras ha aumentado en general, y 2023 anuncia una importante inversión de 14 millones de libras del Consejo de Investigación Médica (MRC) y el Instituto Nacional de Investigación Sanitaria y Asistencial (NIHR) del Reino Unido.

  Aunque los enfermos de enfermedades raras se enfrentan a menudo a viajes difíciles, hay esperanza.

The increased focus on research, development, and accessibility of treatments is paving the way for a brighter future. More doctors and clinicians are dedicating their research to rare diseases, increasing the availability of effective and novel treatments. Masters are a empresa farmacéutica mundial that recognises the challenges associated with rare diseases and is committed to increasing accessibility to their medications. We are expert pharmaceutical drug suppliers making medicines available in emerging markets extends to rare diseases. We continually strive to transform lives through the power of medication